Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.
Severity, location, and symptom burden of psoriasis are 3 key factors associated with risk of adverse behavioral health and quality of life issues in patients, said Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics.
Transcript
Can you discuss risk factors for adverse behavioral outcomes in patients with psoriasis?
I think the extent of the disease that a patient has is really important in that, as well as the location, and then their symptoms. So, if we think about those 3 factors, the extent of disease—obviously if a patient only has the typical plaque psoriasis locations and it's a very low percentage of their overall body surface area (BSA) or maybe it's in an area that is easily hidden from public viewing during their regular week, then the impact of that on their quality of life may be somewhat less. We certainly see a correlation between that and more severe disease, and severe disease usually means higher BSA. And so that's one aspect that I think is important.
The other one is the location. So, we talked about intertriginous psoriasis as a key location. Obviously, and even in our Harris Poll data, we found out that intertriginous disease has a big impact on those intimate aspects of a patient's life. So, sexual function, comfort with engaging in sexual activity—those are impacted by a patient having intertriginous psoriasis, because although it may not be visible to people in your daily life, in those moments, it becomes very important to you. And that's an important aspect of life and something that oftentimes patients might not be talking about.
And then the third aspect, I would say, is really the symptoms. So, if a patient is very symptomatic, and the number one symptom is itch in psoriasis, then that's going to have an impact on their quality of life and can kind of repeatedly disrupt their normal activities throughout the day because they're focusing more so on their psoriasis than on what they're meant to be paying attention to in their work or in caring for their family or whatever it is that they spend their day doing.
Hospital Stays and Probable Dementia as Predictors of Relocation to Long-Term Care Facilities
October 22nd 2024This article explores late-life relocations in patients with dementia, hospital stays, and their implications for health care policy, geriatric care, and future research priorities.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More
FLT3 Inhibitor Gilteritinib May Also Be Effective as ALK Inhibitor in AML
October 20th 2024The case study, which showed prolonged disease control achieved with gilteritinib in a previously-treated patient with AML with an inv(2)(p23q13) translocation, indicates that gilteritinib can also be used as an anaplastic lymphoma kinase (ALK) inhibitor.
Read More